Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-0249 for EDS in OSA
NCT00620659Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Feb 2008
- Primary completion
- Feb 2009
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of MK-0249 in Excessive Daytime Sleepiness (EDS), sponsored by Merck & Co.. Started Feb 2008; status: terminated.
02
Drugs
MK-0249
03
Conditions
Excessive Daytime Sleepiness (EDS)
Beyond the preview
Go deeper on NCT00620659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00620659.